APA (7th ed.) Citation

DL, Y., C, Q., N, P., SP, L., YQ, Y., JL, N., . . . JH, Z. (2026). Neoadjuvant transarterial chemoembolization with tyrosine kinase and immune checkpoint inhibitors improves survival from resectable hepatocellular carcinoma in a multicenter, retrospective study (GUIDANCE002). Communications medicine, 6(1), . https://doi.org/10.1038/s43856-025-01303-w

Chicago Style (17th ed.) Citation

DL, Yang, et al. "Neoadjuvant Transarterial Chemoembolization with Tyrosine Kinase and Immune Checkpoint Inhibitors Improves Survival from Resectable Hepatocellular Carcinoma in a Multicenter, Retrospective Study (GUIDANCE002)." Communications Medicine 6, no. 1 (2026). https://doi.org/10.1038/s43856-025-01303-w.

MLA (9th ed.) Citation

DL, Yang, et al. "Neoadjuvant Transarterial Chemoembolization with Tyrosine Kinase and Immune Checkpoint Inhibitors Improves Survival from Resectable Hepatocellular Carcinoma in a Multicenter, Retrospective Study (GUIDANCE002)." Communications Medicine, vol. 6, no. 1, 2026, https://doi.org/10.1038/s43856-025-01303-w.